Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 147 posts found.

gsk_hq_close

GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

September 13, 2016
Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …

News
johnson_and_johnson_jj

Janssen’s New Drug Application for drug to treat intestinal worms gets US FDA priority review

July 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Johnson & Johnson, US FDA, WHO, drug trial, new drug application, regulation, soil-transmitted helminthiasis

Johnson & Johnson (NYSE: JNJ) said the US Food and Drug Administration (FDA) has granted Priority Review for its New …

News
jj_sign_on_wall

J&J raises FY outlook, Q1 beats estimates

April 20, 2016
Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales

Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …

News
janssen_latest_logo_on_sign

Janssen slams NICE decision on Imbruvica

March 2, 2016
Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …

News
talc

J&J fined $72 million in talc cancer case

February 24, 2016
Research and Development, Sales and Marketing Johnson & Johnson

A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, …

News
Xarelto

Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …

News
ebola_virus

Johnson & Johnson begins Ebola vaccine trial in Sierra Leone

October 14, 2015
Research and Development Ebola vaccine, Johnson & Johnson

Johnson & Johnson has begun a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen …

News
fda_building

FDA strengthens safety warning for J&J’s diabetes drug Invokana

September 14, 2015
Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …

News

Janssen sales follow J&J’s downward trend

July 15, 2015
Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio

Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …

News
J&J image

J&J profits down in Q3

October 17, 2012
Sales and Marketing J&J, JJ, Johnson & Johnson, Q3, Risperdal

Johnson & Johnson has reported a 6.5% year-on-year sales increase to $17.1 billion in the third quarter of 2012, a …

News

Pharma creates non-profit R&D organisation

September 21, 2012
Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma

Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …

News

J&J buys into Genmab cancer drug

August 31, 2012
Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma

Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …

News

Sheri McCoy resigns from Johnson & Johnson

April 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Johnson & Johnson, Sheri McCoy, resignation

Johnson & Johnson has announced that Sheri McCoy, vice chairman of the executive committee, will leave the company on April …

Appointment
Zytiga

European approval for prostate cancer drug Zytiga

September 8, 2011
Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …

News

Xarelto receives FDA approval

July 4, 2011
Sales and Marketing Bayer, Eliquis, Johnson & Johnson, Pradaxa, Xarelto, anticoagulant

Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025